News
Ara Parseghian Medical Research Conference
Members of the Warren Center in attendance at the annual Ara Parseghian Medical Research Conference in Tucson, AZ in early June.
…
Spring 2019 The Warren Roundup
As the 2018 academic year comes to an end, a summary of this year's accomplishments is provided in the annual Warren Roundup. First of all, several lead compounds have been identified by Notre Dame researchers and are undergoing preclinical evaluation, in hopes of identifying investigational new drugs (IND) for clinical evaluation. …
Notre Dame's Warren Center for Drug Discovery collaborates with Perlara on screening platform for glycogen storage diseases
Perlara, a rare diseases drug discovery company based in the San Francisco Bay area, recently announced a collaboration called PerlQuest with the University of Notre Dame’s Warren Family Research Center for Drug Discovery and Development.
Notre Dame technology licensed worldwide: Hsiri Therapeutics enters into a license and research collaboration agreement with Shionogi &Co., Ltd. for the treatment of mycobacterial diseases
University of Notre Dame licensee Hsiri Therapeutics, Inc., with its corporate headquarters located in Media, PA, has entered into a license agreement with Shionogi & Co., Ltd. regarding a collaborative licensing, research and development program to discover and develop novel therapeutics for non-tuberculous mycobacterial (NTM…
New Hope for the Treatment of Diabetic Foot Ulcers
In America, more than a million people suffer from diabetic foot ulcers.
In Latin, SalvePeds means “saving feet.”
And in SalvePeds, a new IDEA Center startup managed and marketed by a team of graduate students at the University of Notre Dame, patients may soon have a more effective option to treat diabetic foot ulcers and prevent some of the 100,000 amputations the condition necessitates every year.…
Spring 2018 Warren Roundup Published
Welcome to the first edition of the Warren Roundup, wherein an attempt is made to summarize accomplishments by members of the Warren Family Research Center for Drug Discovery. In addition, you will find below a succinct summary of the services provided by each of the three scientific cores (synthesis, computational, and biological). Not only do I invite you to provide updates for inclusion in upcoming issues, but I also encourage you to learn more about the Warren Center cores and how they can help expedite your research.…
Indiana CTSI launching new program to engage Indiana residents in improving health through research
The Indiana Clinical and Translational Sciences Institute (CTSI), a research partnership among Indiana University, Purdue University and the University of Notre Dame, has launched a new program called “All IN for Health” to help grow public awareness of the state’s current health challenges and to invite the public’s participation into research studies taking place at our academic partner institutions.
Indiana CTSI Receives $33M NIH Grant to Improve Health Statewide, with Public’s Participation
Indiana’s preeminent research universities are collaborating through the Indiana Clinical and Translational Sciences Institute (CTSI), which has recently been awarded more than $33 million in renewed National Institutes of Health (NIH) funding for the next five years.
Brian Blagg appointed new director of Warren Center for Drug Discovery
Brian Blagg, Ph.D., currently the Lester and Betty Mitscher Professor of Medicinal Chemistry at the University of Kansas, will join the University of Notre Dame as the incoming director of the Warren Family Research Center for Drug Discovery and Development and the Charles Huisking Professor of Chemistry & Biochemistry, according to Mary E. Galvin, William K. Warren Dean of the College of Science.
Researchers Shed New Light on Influenza Detection
Researchers have discovered a way to make influenza visible to the naked eye, by engineering dye molecules to target a specific enzyme of the virus.
Apply Today for these open Indiana CTSI Grants
There are currently four open Indiana Clinical and Translational Sciences Institute grant opportunities.
The Indiana CTSI is seeking applicants for the Collaboration in Translational Research (CTR) Pilot Grant Program. The objective of the Indiana CTSI CTR pilot grant program is to foster and encourage collaboration across the Indiana CTSI partner institutions (IU, Purdue, and Notre Dame) and to initiate or continue translational research projects that have very strong and immediate potential to develop into larger, externally funded research programs, or generate novel intellectual property (IP).
Tuberculosis Research Sheds Light on Disease-related Protein
The WHO names Tuberculosis (TB) as one of the top 10 causes of death worldwide and over 95 percent of those deaths occur in low- and middle-income countries. To improve the global health community’s understanding of TB and provide information that could help treat it, Notre Dame researchers have developed a new strain of the bacteria along with a new method to better study this deadly disease.
Warren Center faculty member presents at the Solutions for Drug-Resistant Infections Conference (SDRI 2017)
Professsor Marv Miller presented the seminar, “Conjugation of an acinetobacter selective sideophore to Daptomycin generates a sideromycin with potent activity against acinetobacter baumannii” at the Antimicrobial Drug Discovery Symposium at the Solutions for Drug-Resistant Infections (SDRI) conference in Brisbane, Australia, April 3-5. SDRI 2017 brought together leading scientific, medical and…
ND Day 2017: Supporting the Warren Family Research Center for Drug Discovery & Development
The College is thrilled to announce that Brian Blagg (currently the Lester and Betty Mitscher Professor of Medicinal Chemistry at Kansas), will be joining the Department of Chemistry & Biochemistry this Fall and assuming the role of Director of the Warren Family Research Center for Drug Discovery & Development. …
WHO's list of Priority Pathogen's and Antibiotic Research in the Warren Center
February 28, 2017 - For the first time, the World Health Organization (WHO) published a list of “priority pathogens” which constitute a current and extreme threat to human health. WHO is seeking to promote new efforts in the discovery and development of new antibiotics to address a growing threat of antibiotic resistance.…
Expanding new areas of rare disease research at Notre Dame
Coinciding with the World Rare Disease Day, Notre Dame acknowledges a recent, generous gift from Notre Dame parents David and Cathleen Reisenauer of Morgan Hill, Calif., which will allow the Warren Family Research Center for Drug Discovery and Development to initiate a new area of research, focusing on the rare disease glycogen storage disease type III (GSDIII), also known as Cori Disease.
Rare Disease Day a Reminder of the Importance of Research
The University of Notre Dame’s Warren Family Research Center for Drug Discovery and Development is focusing on collaboration, as it continues a rich history in therapeutic discovery.
Rare Disease Day 2017 and Rare Disease Research within the Warren Center
Rare Disease Day takes place annually on the last day of February. Its goal is to raise awareness amongst the general public and policy-makers. Global Genes maintains the RARE List™ of 7,000 rare diseases defined in the United States where a prevalence of less than 200,000 cases is the primary criteria. With about 25M Americans affected by a rare disease and the potential to increase our understanding of more common afflictions, rare disease research is a key to better health for all of us.…
International collaboration provides Notre Dame students with unparalleled opportunity
For decades, professor Paul Helquist has partnered with colleagues in Sweden to send undergraduate and graduate chemistry students to each others’ laboratories—around 50 in total—to perform research at Notre Dame, the University of Stockholm, Gothenburg University, the Royal Institute of Technology in Stockholm as well as the Astra Zeneca pharmaceutical lab near Gothenburg. Students from Notre Dame obtain valuable experience working in an international lab in a country which has a long-standing, strong program in science and engineering, particularly chemistry.